Radiopharm (ASX:RAD) reports encouraging additional data from brain metastases imaging trial

November 23, 2022 12:09 PM AEDT | By Aditi Sarkar

Google News:

Radiopharm (ASX:RAD) reports encouraging additional data from brain metastases imaging trial — Image source: company update

Recent News

68% of Organizations Under Attack: New Report from CoreView Reveals Mi...

Obsidian Security Expands Go-to-Market Leadership Team to Scale SaaS P...

Prioritizing Korean Guests, 2025 'Shanghai Summer' Launches with 300+...

2025 'Shanghai Summer' Launches: Smart City Integration and Multicultu...

Highlights

Radiopharm’s shares gained more than 4% in the early hours of 23 November post a new update on Phase II imaging trial in brain metastases.

Additional data related to F-18 Pivalate in Phase II imaging trial on brain metastases showed maximum standardised uptake within lesions.

Radiopharm’s CEO stated that obtaining a quality image implies another positive step for the potential of the Pivalate technology for the company.

Radiopharm Theranostics (ASX:RAD) has provided an upbeat update concerning F-18 Pivalate (RAD 101), its lead product candidate for brain metastases.

The company stated that Imperial College London has provided further data related to the Phase 2a imaging trial of the compound in patients with brain metastases.

High contrast images seen at 60 minutes after the injection of Pivalate showed the maximum standardised uptake within lesions. The results were significantly different compared to the mean.

Image source: Company update

Image description: High contrast images seen after Pivalate injection

As per the company’s CEO Riccardo Canevari, this is a promising indication and yet another positive step for the potential of the Pivalate technology for Radiopharm.

More to come…

Shares of Radiopharm were trading at AU$0.120 with an uptick of around 4.347% in the early hours of 23 November 2022.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.